- Home
- STTK vs ATRA Comparison
STTK vs ATRA Comparison
Compare STTK & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ATRA
- Stock Information
- Founded
- STTK 2016
- ATRA 2012
- Country
- STTK United States
- ATRA United States
- Employees
- STTK N/A
- ATRA N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STTK Health Care
- ATRA Health Care
- Exchange
- STTK Nasdaq
- ATRA Nasdaq
- Market Cap
- STTK 37.6M
- ATRA 40.1M
- IPO Year
- STTK 2020
- ATRA 2014
- Fundamental
- Price
- STTK $0.83
- ATRA $8.68
- Analyst Decision
- STTK Hold
- ATRA Buy
- Analyst Count
- STTK 4
- ATRA 5
- Target Price
- STTK $3.00
- ATRA $17.75
- AVG Volume (30 Days)
- STTK 401.8K
- ATRA 41.2K
- Earning Date
- STTK 07-31-2025
- ATRA 08-11-2025
- Dividend Yield
- STTK N/A
- ATRA N/A
- EPS Growth
- STTK N/A
- ATRA N/A
- EPS
- STTK N/A
- ATRA N/A
- Revenue
- STTK $4,606,000.00
- ATRA $199,732,000.00
- Revenue This Year
- STTK N/A
- ATRA N/A
- Revenue Next Year
- STTK N/A
- ATRA N/A
- P/E Ratio
- STTK N/A
- ATRA N/A
- Revenue Growth
- STTK 69.65
- ATRA 475.53
- 52 Week Low
- STTK $0.69
- ATRA $5.01
- 52 Week High
- STTK $4.99
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- ATRA 57.82
- Support Level
- STTK $0.77
- ATRA $7.54
- Resistance Level
- STTK $0.91
- ATRA $8.25
- Average True Range (ATR)
- STTK 0.08
- ATRA 0.48
- MACD
- STTK -0.02
- ATRA -0.04
- Stochastic Oscillator
- STTK 16.23
- ATRA 64.09
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).